Safety study comparing two types of hormonal contraceptives
Official title: International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study
Run by Center for Epidemiology and Health Research, Germany · NCT06028555 · Data updated 2026-11-12
This study is testing whether a new hormonal birth control pill is safer than traditional options for women starting these contraceptives.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 101000 (estimated) |
| Sponsor | Center for Epidemiology and Health Research, Germany Academic / other |
| Locations | 1 site (Berlin, State of Berlin) |
| Status | Recruiting |
| Started | June 28, 2023 |
| Main results expected | October 31, 2028 |
| Study ends | October 31, 2028 |
| Registry record updated | August 17, 2025 |
| Trial ID | NCT06028555 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are new users of hormonal contraceptives, specifically those prescribed E4/DRSP or EE/LNG.
✕Probably not a fit
Patients who are not new users of these contraceptives or those using them outside of on-label indications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multinational, observational study aims to compare the safety profiles of a new oral contraceptive containing estetrol (E4) and drospirenone (DRSP) against traditional combined oral contraceptives containing ethinyl estradiol (EE) and levonorgestrel (LNG). It will follow two cohorts of new users of these contraceptives over one to two years, focusing on the incidence of venous thromboembolism (VTE) and other related outcomes. The study will utilize a non-interventional approach, gathering data through healthcare professionals and direct participant contact to ensure comprehensive and accurate reporting of outcomes.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety of a new contraceptive option, potentially reducing the risk of serious side effects for users.
How similar studies have gone: Other studies have explored the safety of hormonal contraceptives, but this specific comparison of E4/DRSP with EE/LNG is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: New users of E4/DRSP New users of EE/LNG Germany: only recruitment of study participants who are prescribed the COC within on-label use Exclusion Criteria: \-
Where it's running
-
Berlin Center for Epidemiology and Health Research
Berlin, State of Berlin, Germany Recruiting
Study contacts
- Principal investigator: Klaas Heinemann, Dr. — ZEG Berlin GmbH
- Study coordinator: Armin Papkalla, Dr.
- Email: a.papkalla@zeg-berlin.de
- Phone: +49 30 945 101 20
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effectiveness of the Natural Cycles birth control app
This study will test how well the Natural Cycles app prevents pregnancy over one year in sexually active women aged 18 to 35 with no known infertility.
-
Female Reproductive Health in the Canadian Armed Forces: Understanding Issues from Contraception to Pelvic Floor Dysfunction
This observational study looks at reproductive health among women in the Canadian Armed Forces to see how contraception, pregnancy outcomes, infertility, pelvic floor issues, and related factors affect service members and veterans.
-
Long-acting HIV PrEP and contraception PK study in AGYW
This study tests how long-acting cabotegravir for PrEP interacts with hormonal contraception in young women.
-
Vasectomy: Right for Me? — a web-based decision aid
A web-based decision aid helps men think clearly about vasectomy and other birth control options to see if it fits their goals.
-
Contraceptive patch designed to stop ovulation
This trial tests whether a norelgestromin transdermal patch can keep ovulation suppressed for 84 days even when users make intentional application mistakes, in healthy women aged 18–35.
-
Helping teens and young adults choose menstrual care and birth control
This project will try an Encounter Decision Aid to help adolescents and young adults (ages 12–25) make decisions about menstrual management and contraception during outpatient visits.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.